Evaluating a New Class of AKT/mTOR Activators for HIV Latency-Reversing Activity Ex Vivo and In Vivo

An ability to activate latent human immunodeficiency virus type 1 (HIV-1) expression could benefit many HIV cure strategies; however, most latency-reversing agents (LRAs) have proven disappointing. We evaluated AKT/mTOR activators as a potential new class of LRAs. Two glycogen synthase kinase-3 inhi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Virol
Main Authors: Gramatica, Andrea, Schwarzer, Roland, Brantley, William, Varco-Merth, Benjamin, Sperber, Hannah S., Hull, Philip A., Montano, Mauricio, Migueles, Stephen A., Rosenthal, Danielle, Hogan, Louise E., Johnson, Jeffrey R., Packard, Thomas A., Grimmett, Zachary W., Herzig, Eytan, Besnard, Emilie, Nekorchuk, Michael, Hsiao, Feng, Deeks, Steven G., Snape, Michael, Kiernan, Bernard, Roan, Nadia R., Lifson, Jeffrey D., Estes, Jacob D., Picker, Louis J., Verdin, Eric, Krogan, Nevan J., Henrich, Timothy J., Connors, Mark, Ott, Melanie, Pillai, Satish K., Okoye, Afam A., Greene, Warner C.
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2021
Assuntos:
Vaccines and Antiviral Agents
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8103695/
https://ncbi.nlm.nih.gov/pubmed/33536176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.02393-20
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares